South Korea's Abortion Pill Debate Stalls Between Drug Approval and Unfinished Laws

Six years after the ruling, patients still lack a clear route to care

South Korea has removed criminal penalties for abortion, but it has yet to build a comprehensive medical system around that change. As of September 7, 2025, mifepristone remains unapproved, lawmakers are considering new legislation, and patients face a choice between costly surgery at willing clinics and unapproved pills bought online.

The Constitutional Court ruled in 2019 that criminal penalties for abortion were unconstitutional and ordered lawmakers to replace the old framework by the end of 2020. Parliament missed that deadline. Abortion became decriminalized in January 2021, leaving the country without clear rules governing how, when and where patients can receive care.

The Maternal and Child Health Act still contemplates only limited exceptions, including pregnancies resulting from rape or incest. Hospitals often turn away patients who fall outside those conditions. Without official protocols, training and insurance coverage, providers have little practical support for establishing abortion services.

Patients with fewer resources face the greatest difficulty. Minors, families with low incomes and people outside major cities may need to travel long distances, pay rising bills and sort through unreliable information. Some turn to underground markets, where smuggled or counterfeit medication can cause complications.

Decriminalization removed the threat of prosecution for ending a pregnancy. A health care framework would do something different: establish clinical standards, explain providers' responsibilities and make access and payment more predictable. South Korea has completed the first change while leaving the second unfinished.

The main legal milestones show how that gap developed:

• 2019: The Constitutional Court ruled that criminal penalties for abortion were unconstitutional.
• December 2020: The deadline for replacement legislation passed without Parliament adopting a new framework.
• January 2021: Abortion became decriminalized.
• Summer 2025: Lawmakers introduced proposals to recognize medication abortion and provide insurance coverage.

Why mifepristone is central to the debate

Mifepristone is used with misoprostol to end an early pregnancy. The combination has been used for decades in more than 90 countries and appears on the World Health Organization's list of essential medicines. In South Korea, the absence of approval for mifepristone leaves patients dependent on surgery or medication obtained outside regulated channels.

Mifepristone blocks progesterone, the hormone that maintains a pregnancy. Misoprostol then causes the uterus to contract and expel its contents. Where the regimen is approved, clinicians and public health agencies provide guidance on who can use it, dosing, warning signs and follow up.

Many countries allow the regimen during early pregnancy, often up to 10 or 12 weeks, with clinical discretion for specific cases. Health services also provide counseling, information about managing pain and instructions on when to seek emergency care. Regulated access places the process within a system of medical guidance and support.

International health data cited by physicians and rights groups put the risk of serious side effects from medication abortion typically below 0.5 percent. They also associate access to approved pills with less demand for surgical procedures and reduced reliance on unsafe methods.

The World Health Organization estimates that about 73 million abortions take place worldwide each year, of which about 25 million are unsafe. Clinicians see supervised access to medication as a practical way to reduce harm. In South Korea, where unapproved pills circulate online, regulation could address preventable risks arising from poor quality control while giving patients another option when surgical providers are difficult to reach.

Drug regulators are waiting for legislation

The Ministry of Food and Drug Safety has not approved Mifegymiso, a combination of mifepristone and misoprostol made by LinePharma and widely used overseas. Hyundai Pharm signed an exclusive supply agreement with the manufacturer and filed product applications in 2021 and 2023, followed by a third application in December 2024.

Ministry officials say the review cannot reach a final decision because lawmakers have not defined medication abortion as a legal medical service. They want legislation setting rules on the stage of pregnancy at which it may be used, clinical indications and requirements for managing risks.

The ministry says those rules are needed to finalize decisions on effectiveness, dosing, labeling and monitoring after the product enters the market. Monitoring after approval allows regulators to track how a medicine performs once it is used in routine care.

Officials have not chosen conditional approval or a pathway allowing restricted use of Mifegymiso. They say a legislative framework and social consensus must come first. Hyundai Pharm also acknowledges the difficulty of advancing approval before lawmakers act.

Patients and clinicians are left in a policy loop: the medicine awaits rules, while progress on those rules has been hindered partly by the medicine's absence from the health system. The product remains under review, with no clear timeline for a decision.

What the proposed health law would change

Lawmakers shifted the debate during summer 2025 by introducing measures to recognize abortion by medication as a legal medical procedure. A proposal to amend the Maternal and Child Health Act would define abortion as the termination of pregnancy through surgical or pharmaceutical methods, moving beyond the law's narrow exceptions.

The proposal also calls for national health insurance coverage. That would address a central barrier for patients who can find a willing provider but cannot afford treatment. Sponsors have argued for removing outdated requirements such as spousal consent and bringing terminology into line with international medical practice.

President Lee Jae Myung's administration has placed abortion medication on its national policy agenda for the next five years. That gives the issue a place in the government's stated priorities, alongside the legislative proposals now under discussion.

A revised health law would answer questions left open since the 2019 ruling: which services providers can offer, what clinical eligibility rules apply, how treatment is paid for and who oversees it. Clinicians need those answers to provide care without fear of professional sanctions or civil liability. Patients need them to find dependable information and affordable treatment.

The central change would be practical. Instead of leaving each patient to locate a clinic willing to navigate uncertain rules, a defined medical framework would give providers and patients a common set of standards.

Costs and shortages narrow patients' choices

Surveys show that about 40 percent of abortion patients paid more than one million won for a surgical procedure. Advocates and clinicians describe rising costs that can force people to delay care. A delay can narrow the available options and make treatment more medically complex.

An obstetrician at the National Medical Center has described abortion services as a luxury for many people excluded from mainstream systems. The financial burden sits alongside other obstacles: finding a provider, arranging travel and obtaining reliable information about treatment.

Adolescents, migrants, people with disabilities and residents far from major hospitals face particularly difficult conditions. Families with low incomes have less room to absorb a large medical bill or the cost of traveling to another city.

A series of trainee doctor resignations reduced obstetrics and gynecology capacity in 2025, placing further pressure on clinics that still accept abortion patients. Fewer trained providers, combined with unclear professional protections, make hospitals reluctant to add services.

Many health systems use medication abortion to broaden access through primary clinics and ease pressure on surgical services. South Korea cannot draw on that option through an approved system while mifepristone remains unapproved. For patients, the combination of staffing shortages and legal uncertainty can mean fewer places to seek timely care.

The information gap extends to the internet

Women on Web, a nonprofit that supports medication abortion in countries with restricted services, had its website blocked in South Korea in 2019 under the Pharmaceutical Affairs Act. In May 2024, a South Korean court rejected an appeal to lift that block.

Civil society groups argue that the government has failed to create a safe route to legal care while restricting online information used by people seeking help. Health officials say they must first establish a legal and regulatory framework before changing drug policy. That position has kept the existing arrangements in place for years.

The website restriction sits alongside the wider shortage of dependable public guidance. Patients already facing uncertain clinic access and high costs must also decide which online information and products they can trust. Advocates want digital policy and health policy to work toward the same goal: reliable guidance and safer access to care.

Rights advocates and opponents press different priorities

Human Rights Watch and domestic groups have called on the government to put abortion access into law, approve medication abortion and remove barriers to trustworthy information. Their demands focus on turning the removal of criminal penalties into a functioning health service.

The National Human Rights Commission of Korea recommended in 2024 that mifepristone be introduced and designated as an essential medicine, bringing national policy into line with World Health Organization standards.

International medical voices, including physicians from Women on Web, describe abortion as a fundamental part of sexual and reproductive health. They argue that access should not depend on a patient's income, location or marital status.

Religious organizations and some professional groups oppose wider access or seek tighter limits. Catholic leaders recently submitted formal objections to lawmakers, calling for harmony between fetal life and a woman's self determination.

The Catholic leaders strongly oppose any framework they believe would allow procedures late in pregnancy and have criticized extending national health insurance to abortion care. Those positions have shaped public hearings and are likely to affect whether legislative committees revise or slow the proposals. Lawmakers are therefore considering both the practical demands of patient care and competing views about the limits of that care.

Cases late in pregnancy expose unresolved legal rules

A vlogger's claim in 2024 that she ended a pregnancy at 36 weeks prompted a police investigation and widespread controversy. The case brought attention to the absence of defined gestational limits, meaning limits based on how far a pregnancy has progressed.

Experts noted that although the old abortion crimes had expired, homicide charges could still be tested if evidence suggested a live birth. The legal issue in such circumstances would turn on evidence about what happened during the procedure and whether a baby was born alive.

In 2025, a doctor was arrested in connection with a termination at nine months of pregnancy. That case renewed attention to the lack of clear clinical rules and statutory limits.

Such dramatic cases are rare, yet they can dominate public discussion more than the routine needs of patients seeking care. Clinicians face uncertainty about the legal boundaries of practice. Patients may fear unwanted scrutiny or a provider refusing treatment at the last minute. Clear legislation would give the debate a defined set of medical and legal rules.

Requests for help show that demand continues

A retrospective study of consultations submitted to Women on Web from South Korea between 2013 and 2019 counted more than 12,000 requests. The median age was 25, and the median gestational age was just over five weeks. A median is the middle value when the ages or stages of pregnancy are arranged in order.

People seeking help cited financial hardship, a wish to continue their education and a lack of readiness to become parents as leading reasons. Researchers concluded that restrictive rules do not stop abortion; they move care into private and often less safe channels. Reducing that reliance is one of the goals lawmakers say they want to achieve.

South Korea's experience fits a broader pattern in which removing criminal penalties without building a health care framework leaves uneven access, provider confusion and room for unregulated markets. In Latin America, some countries have adopted clear statutory models with defined timelines and reasons for care, while others retain severe restrictions.

Even where abortion is permitted, reluctant providers, documentation requirements and weak clinic networks can prevent patients from obtaining it. Consistent guidance, legal protections for providers and reliable coverage help reduce delays. South Korea's debate therefore concerns both legal permission and the everyday arrangements that make treatment available.

What a functioning system would need

Countries that have integrated medication abortion into health services offer lawmakers several models. They set gestational limits for routine use, standardize dosing and follow up, and establish referral routes for complications. These arrangements explain where routine care ends and when another provider or hospital should take over.

Those systems also clarify conscientious objection, which allows individual clinicians to decline participation because of their beliefs, while ensuring that institutions maintain access to services. Training across primary and specialty care helps patients find treatment closer to home.

Patient privacy and optional counseling are other parts of such frameworks. Counseling can support someone who wants it without becoming an obstacle that delays care. The aim is to connect information, treatment and medical support in a predictable process.

For South Korea, the priorities identified by experts begin with defining abortion as a medical service delivered through surgical or pharmaceutical methods. Approval of mifepristone and misoprostol would need to be accompanied by clear clinical guidance. National health insurance coverage would help prevent cost from becoming a practical barrier.

Providers also need professional protections so hospitals can establish services without fear of legal exposure. Accurate public information channels would address the guidance gap, including the difficulties created by blocking trusted online resources. Bringing digital policy into line with health goals would help people obtain dependable advice rather than turn to risky sellers.

These steps would not require agreement on every moral question surrounding abortion. They would require the government to establish transparent rules for safe and predictable care. Six years after the Constitutional Court's ruling, that remains the central unfinished task.

Key Points

• Abortion became decriminalized in January 2021, but South Korea still lacks a comprehensive health care framework.
• Mifepristone remains unapproved. Regulators say legislation is needed before they can finalize a decision.
• Hyundai Pharm filed applications for Mifegymiso in 2021, 2023 and December 2024.
• Proposed legislation would recognize surgical and medication abortion and provide national health insurance coverage.
• About 40 percent of patients in surveys paid more than one million won for surgical care.
• Provider shortages and uncertain professional protections restrict access, especially for people with fewer resources.
• The Women on Web website was blocked in 2019, and a court rejected an appeal to lift the block in May 2024.
• Rights groups seek approval and clearer access rules, while Catholic leaders and other opponents seek limits.
• Cases involving pregnancies at 36 weeks and nine months have intensified debate over undefined legal boundaries.
• International data put serious side effects from medication abortion typically below 0.5 percent.
• A functioning system would combine clinical standards, approved medication, insurance coverage, provider protections and reliable information.